Related Experiment Video
Updated: May 12, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Low frequency of N-methyl-D-aspartate receptor autoimmunity in tick-borne encephalitis
Jakob Morén1,2, Barbro Persson3, Anna Sörman3
1Infection Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Background:
Tick-borne encephalitis is a viral infection of the central nervous system that may cause severe illness and long-term sequelae, to which underlying mechanisms are not completely understood. Autoantibodies against the N-methyl-D-aspartate receptor (anti-NMDAR) may be triggered by immunologic events, occur sporadically, and can cause autoimmune encephalitis. Following herpes simplex encephalitis and Japanese encephalitis, anti-NMDAR autoantibodies may develop and have been associated with relapse or impaired cognitive recovery. Tick-borne encephalitis has been shown to trigger anti-NMDAR encephalitis in sporadic cases, but the frequency of autoimmunization is unknown.
Objectives:
The objective of this study was to assess the frequency of intrathecal anti-NMDAR antibody development following tick-borne encephalitis and to explore whether such antibodies could be relevant to cognitive complaints.
Methods:
Adult patients with tick-borne encephalitis were included retrospectively from one cohort and prospectively from another. A stored post-acute cerebrospinal fluid sample was required for anti-NMDAR analysis. Two commercial kits (Euroimmun AG, Lübeck, Germany) were used to detect anti-NMDAR IgG antibodies in cerebrospinal fluid.
Results:
A total of 71 cerebrospinal fluid samples from 53 patients were analyzed for anti-NMDAR antibodies. Samples were obtained at a median of 91 days (range 21-471) after onset of central nervous system symptoms. Anti-NMDAR antibodies were detected in two samples from a single tick-borne encephalitis patient, corresponding to 1.9% of patients (95% CI: 0.05-10.1%).
Conclusions:
The development of intrathecal anti-NMDAR autoantibodies following tick-borne encephalitis is a rare event, and further studies are needed to clarify their potential relevance to cognitive outcomes in a minority of cases. Testing for anti-NMDAR antibodies in cerebrospinal fluid may be considered in patients who experience clinical deterioration following an initial recovery.
Insights
Autoantibodies against the N-methyl-D-aspartate receptor (anti-NMDAR) rarely develop after tick-borne encephalitis. Further research is needed to understand their role in cognitive issues in some patients.
Area of Science:
- Neuroimmunology
- Infectious Diseases
- Neurology
Background:
- Tick-borne encephalitis (TBE) is a central nervous system viral infection with poorly understood mechanisms and potential long-term effects.
- Autoimmune encephalitis, characterized by autoantibodies against the N-methyl-D-aspartate receptor (anti-NMDAR), can be triggered by various events and may complicate recovery from other encephalitides.
- While TBE has been anecdotally linked to anti-NMDAR encephalitis, the frequency of this autoimmunization is unknown.
Purpose of the Study:
- To determine the frequency of intrathecal anti-NMDAR antibody development post-TBE.
- To investigate the potential association between anti-NMDAR antibodies and cognitive complaints in TBE patients.
Main Methods:
- Retrospective and prospective analysis of adult patients diagnosed with TBE.
- Detection of anti-NMDAR IgG antibodies in cerebrospinal fluid (CSF) using two commercial kits.
- Analysis of 71 CSF samples from 53 patients, collected a median of 91 days post-symptom onset.
Main Results:
- Anti-NMDAR antibodies were detected in CSF samples from one TBE patient.
- This represents an incidence of 1.9% (95% CI: 0.05-10.1%) of the studied TBE patient cohort.
- The positive samples were identified using Euroimmun AG kits.
Conclusions:
- Intrathecal anti-NMDAR autoantibody development following TBE is infrequent.
- The clinical significance of these antibodies for cognitive outcomes in a subset of patients requires further investigation.
- Consideration of anti-NMDAR antibody testing in CSF may be warranted for TBE patients experiencing post-recovery clinical decline.
More Related Videos
Related Concept Videos
Arboviral Encephalitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology

